Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Reichman

Showing results (251-260 of 301) with videos related to

Pageof 31
Sort By:
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapyM Markman, W Jones, J L Lewis, et al.
Gynecologic Oncology|May 1, 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatmentM Markman, T Hakes, B Reichman, et al.
Cancer|February 15, 1993
Intraperitoneal chemotherapy in the management of ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicityP Francis, M Markman, T Hakes, et al.
Gynecologic Oncology|December 11, 1992
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapyM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerM Markman, T Hakes, B Reichman, et al.
Cancer|January 15, 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experienceM Markman, J L Lewis, P Saigo, et al.
Pageof 31

Showing results (251-260 of 301) with videos related to

Sort By:
Pageof 31
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapyM Markman, W Jones, J L Lewis, et al.
Gynecologic Oncology|May 1, 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatmentM Markman, T Hakes, B Reichman, et al.
Cancer|February 15, 1993
Intraperitoneal chemotherapy in the management of ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicityP Francis, M Markman, T Hakes, et al.
Gynecologic Oncology|December 11, 1992
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapyM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerM Markman, T Hakes, B Reichman, et al.
Cancer|January 15, 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experienceM Markman, J L Lewis, P Saigo, et al.
Pageof 31